Search clinical trials for: Immune Checkpoint Inhibitor Pneumonitis

Total 110537 results

Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Xinqiao Hospital of Chongqing

Recruiting

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

Pneumonitis

China
Hubei Cancer Hospital

Recruiting

The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors

Cancer Patients

China
M.D. Anderson Cancer Center

Recruiting

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma

United States
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Recruiting

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Immunotherapy | Pneumonitis, Interstitial | Immune-related Adverse Events

Belgium
First Affiliated Hospital Xi'an Jiaotong University
Fujian Cancer Hospital; Henan Cancer Hospital; The First Affiliated Hospital... and other collaborators

Not yet recruiting

Exploration of the Predictive Marker and Establishment of Predictive Models of Checkpoint Inhibitor Pneumonitis

Pneumonia, Interstitial
Maastricht Radiation Oncology
Maastricht University Medical Center; Zuyderland Medical Centre

Completed

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Stage IV Non-small Cell Lung Cancer

Netherlands
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
University of Kansas Medical Center

Not yet recruiting

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Solid Tumor

United States
Acepodia Biotech, Inc.

Not yet recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States
OncoAtlas LLC
N.N. Blokhin National Medical Research Center of Oncology; Moscow MultidisciplinaryClinical...

Recruiting

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy (BLOOMSI)

Cancer | Colorectal Cancer | Colorectal Cancer Metastatic | Colon Adenocarcinoma | MSI-H Colorectal Cancer | dMMR Colorectal Cancer

Russian Federation
Osel, Inc.
City of Hope Comprehensive Cancer Center; Miyarisan Pharmaceutical Co., Ltd.

Recruiting

Dose Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab in Advanced Stage Renal Cell Carcinoma

Advanced or Metastatic Renal Cell Carcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

HCC

China
xiaohua li

Not yet recruiting

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Gastroesophageal Junction Cancer
National Cancer Institute (NCI)

Not yet recruiting

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Colorectal Cancer | Gastroesophageal Cancer

United States
University Hospital, Basel, Switzerland

Not yet recruiting

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (ISCA-CHECK)

Advanced Solid Tumor

Switzerland
Tel Aviv Medical Center

Not yet recruiting

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Triple Negative Breast Cancer
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Zhejiang University

Recruiting

A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

Immune Checkpoint Inhibitors | Liver Injury

China
Twinpig Biolab, Inc.

Not yet recruiting

Clinical Trial of TB511 in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Prostate Cancer
Rise Therapeutics LLC

Not yet recruiting

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Melanoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Melanoma Recurrent | Squamous Cell Cancer | Basal Cell Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CBM588 in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR

Triple-Negative Breast Cancer
The Methodist Hospital Research Institute

Recruiting

IL-2 Plus Abatacept in FTD

Frontotemporal Degeneration

United States
Genmab
BioNTech SE

Recruiting

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Malignant Solid Tumor

Spain
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
University Hospital, Essen
Bristol-Myers Squibb; Advanced Accelerator Applications

Not yet recruiting

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NEPI)

Very High Risk Prostate Carcinoma

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma | Radiotherapy | Pembrolizumab | Tumor Thrombosis

China
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
Amsterdam UMC, location VUmc
Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital

Not yet recruiting

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) (PREOPANC-5)

Borderline Resectable Pancreatic Cancer
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc.

Recruiting

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
University Health Network, Toronto

Not yet recruiting

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Melanoma (Skin)

Canada
Yehua Shen

Not yet recruiting

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

HCC - Hepatocellular Carcinoma
Saint Petersburg State University, Russia

Recruiting

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer

Russian Federation
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Ruijin Hospital

Not yet recruiting

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer (NeoCHIC)

Colon Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Gustave Roussy, Cancer Campus, Grand Paris
Medical University of Vienna; University Hospital, Essen; Fondazione IRCCS Istituto... and other collaborators

Recruiting

CARE1 Pragmatic Clinical Trial (CARE1)

Metastatic Kidney Carcinoma | Metastatic Kidney Cancer

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Lantheus Medical Imaging

Not yet recruiting

PSMA Therapy and Immunotherapy in Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma
7 Hills Pharma, LLC

Not yet recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States

Search clinical trials for: Immune Checkpoint Inhibitor Pneumonitis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations